Artelo Biosciences, Inc. — Q2 2023 Form 10-Q
Reporting period: Three and six months ended June 30, 2023. Financial amounts below are in U.S. dollars; financial statement amounts are in thousands unless otherwise stated.
Business context and reporting period
Artelo is a clinical-stage biopharmaceutical company developing therapeutics targeting lipid-signaling pathways, including the endocannabinoid system. It has no approved products and has not generated revenue.
- ART27.13: In a Phase 1b/2a trial for cancer-related anorexia. Phase 1b enrollment was completed in Q1 2023; the expanded Phase 2a began in the UK in April 2023 and is planned to enroll up to 40 patients, with 3:1 randomization and up to 18 sites across five countries.
- ART26.12: A preclinical FABP5 inhibitor program prioritized for chemotherapy-induced peripheral neuropathy (CIPN).
- ART12.11: A preclinical CBD cocrystal program being explored for potential indications including inflammatory bowel disease and PTSD.
Financial results and liquidity
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| General and administrative expense | $1,032 | $1,415 | $2,089 | $2,897 |
| Research and development expense | $752 | $1,056 | $1,987 | $1,520 |
| Total operating expenses | $1,784 | $2,471 | $4,076 | $4,417 |
| Loss from operations | $(1,784) | $(2,471) | $(4,076) | $(4,417) |
| Other income | $185 | $22 | $309 | $3 |
| Net loss | $(1,599) | $(2,449) | $(3,767) | $(4,414) |
| Basic and diluted loss per share | $(0.56) | $(0.87) | $(1.32) | $(1.56) |
- At June 30, 2023, cash and cash equivalents were $5.719 million and trading marketable securities were $8.272 million; working capital was $13.999 million. Total assets were $16.877 million and total liabilities were $0.609 million. No debt balance is reported; liabilities principally include payables and operating lease obligations.
- Operating cash use was $3.809 million for the six months, compared with $4.019 million in the prior-year period. Investing activities provided $2.598 million, primarily reflecting securities maturities and sales, partly offset by purchases. Cash declined by $1.169 million to $5.719 million.
- The company reported no meaningful product margins because it has no revenue. Operating margin is not meaningful for the same reason.
- UK R&D tax credits received were $1.206 million in the first half of 2023 versus $1.041 million in the first half of 2022; the company recognizes these credits as an offset to R&D expense.
Material changes versus prior comparable periods
- Q2 operating expenses fell $687,000 year over year, with G&A down $383,000 and R&D down $304,000. Management attributed lower G&A mainly to lower noncash stock-based compensation and lower quarterly R&D partly to increased UK tax credits; higher R&D salaries and third-party costs partly offset the latter.
- For the first half, operating expenses decreased $341,000: G&A fell $808,000, while R&D increased $467,000, reflecting increased internal R&D salaries and third-party service-provider payments.
- Net loss improved by $850,000 in Q2 and $647,000 in the first half. Higher gains from changes in the fair value of trading securities contributed to the improvement in other income.
- Cash and cash equivalents declined from $6.888 million at December 31, 2022 to $5.719 million at June 30, 2023; current assets and working capital also declined.
Outlook, risks, and unusual items
- Management expects existing cash resources to fund planned operations into the second half of 2024. Continuing beyond that period requires additional financing or licensing product candidates; management cautions that funding may not be available on acceptable terms or at all.
- A $75 million shelf registration statement became effective July 14, 2023, allowing potential future sales of equity, debt, warrants, or units. The $20 million equity line with Lincoln Park had no sales through June 30; subsequently, the company issued 30,000 shares for approximately $56,000. Future financing may dilute shareholders.
- Management anticipated that first-in-human studies for ART26.12 could begin in the second half of 2024, subject to regulatory review and availability of contract research resources and materials. This is a forward-looking estimate, not a firm commitment.
- The filing identifies the loss of UK R&D tax-credit availability for certain clinical-trial expenditures incurred outside the UK from April 2024 as a potential cost risk. It also cites clinical, regulatory, manufacturing, supply-chain, intellectual-property, controlled-substance, and financing risks.
- The company reports no material pending legal proceedings. Management concluded disclosure controls were effective at a reasonable-assurance level as of June 30, 2023.
Most important facts for investors to verify
- CAReS Phase 2a enrollment, site activation, safety and efficacy updates, and actual timing versus the stated plan.
- Cash burn and investment balances, and whether the stated runway into the second half of 2024 remains achievable.
- Availability and terms of future financing, including use of the shelf registration and equity line, and resulting dilution.
- Impact of UK R&D tax-credit changes on development costs and cash needs from 2024 onward.
- Progress of ART26.12 regulatory-enabling work and whether the conditional second-half 2024 first-in-human target remains feasible.